NASDAQ:BOLT
Bolt Biotherapeutics
- Stock
Last Close
1.10
03/05 20:00
Market Cap
40.62M
Beta: 0.99
Volume Today
38.14K
Avg: 250.78K
PE Ratio
−0.60
PFCF: −0.56
Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|
average inventory | -400K - | ||||||
average payables | 1.49M - | 1.85M 23.64% | 2.59M 40.05% | 3.58M 38.59% | 3.29M 8.19% | ||
average receivables | 1.05M - | ||||||
book value per share | -1.69 - | -3.28 93.60% | -3.30 0.56% | 7.53 328.64% | 4.59 39.07% | 2.98 35.05% | |
capex per share | -0.03 - | -0.04 17.93% | -0.10 182.09% | -0.07 31.24% | -0.05 25.77% | -0.01 89.58% | |
capex to depreciation | -0.96 - | -1.52 57.92% | -5.34 252.07% | -1.96 63.29% | -1.17 40.18% | -0.11 90.67% | |
capex to operating cash flow | 0.03 - | 0.02 34.35% | 0.07 257.56% | 0.04 40.58% | 0.03 37.69% | 0.00 88.39% | |
capex to revenue | -2.36 - | -14.12 497.65% | -1.86 86.86% | -0.34 81.63% | -0.03 92.33% | ||
cash per share | 1.45 - | 2.49 71.97% | 0.72 71.19% | 5.61 682.23% | 4.52 19.41% | 2.70 40.22% | |
days of inventory on hand | |||||||
days payables outstanding | 578.69 - | ||||||
days sales outstanding | 60.25 - | ||||||
debt to assets | 0.00 - | 0.21 8,296.05% | 0.23 11.17% | 0.08 66.13% | 0.10 25.41% | 0.13 27.49% | |
debt to equity | -0.00 - | -0.22 8,754.61% | -0.10 53.35% | 0.10 193.95% | 0.13 35.39% | 0.18 36.03% | |
dividend yield | |||||||
earnings yield | -0.04 - | -0.07 74.31% | -0.07 5.82% | -0.64 809.18% | -1.77 175.52% | -1.63 7.59% | |
enterprise value | 289.22M - | 425.16M 47.00% | 1.03B 142.08% | 159.64M 84.49% | 61.93M 61.20% | 51.76M 16.43% | |
enterprise value over ebitda | -25.88 - | -13.90 46.31% | -27.95 101.10% | -1.87 93.32% | -0.70 62.58% | -0.70 0.30% | |
ev to operating cash flow | -29.30 - | -16.14 44.91% | -21.76 34.80% | -2.80 87.14% | -0.81 71.06% | -0.74 8.04% | |
ev to sales | 1.98K - | 4.46K 125.31% | 126.70 97.16% | 10.81 91.47% | 6.57 39.21% | ||
free cash flow per share | -1.08 - | -1.92 77.89% | -1.59 17.26% | -1.79 12.69% | -2.10 17.36% | -1.84 12.19% | |
free cash flow yield | -0.03 - | -0.06 77.89% | -0.05 17.26% | -0.37 639.40% | -1.62 342.36% | -1.65 1.92% | |
graham net net | -1.94 - | -4.25 118.96% | -4.04 4.96% | 3.87 195.91% | 3.01 22.22% | 1.48 50.75% | |
graham number | 6.85 - | 12.57 83.70% | 12.97 3.16% | 23.09 77.99% | 15.41 33.26% | 11.08 28.09% | |
income quality | 0.85 - | 0.86 1.44% | 0.78 9.84% | 0.58 25.70% | 0.87 50.03% | 1.00 15.70% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | 0 | |
interest coverage | 40.63 - | ||||||
interest debt per share | 0.00 - | 0.73 17,042.14% | 0.34 53.08% | 0.73 114.81% | 0.55 25.61% | 0.53 2.02% | |
inventory turnover | |||||||
invested capital | -0.00 - | -0.22 8,754.61% | -0.10 53.35% | 0.10 193.95% | 0.13 35.39% | 0.18 36.03% | |
market cap | 302.82M - | 449.80M 48.54% | 1.02B 127.63% | 162.66M 84.11% | 48.57M 70.14% | 42.35M 12.80% | |
net current asset value | -17.82M - | -58.39M 227.72% | -126.13M 116.00% | 131.56M 204.31% | 116.44M 11.49% | 58.49M 49.77% | |
net debt to ebitda | 1.22 - | 0.81 33.79% | -0.14 117.99% | 0.04 124.44% | -0.15 525.79% | -0.13 16.02% | |
net income per share | -1.23 - | -2.14 74.31% | -2.27 5.82% | -3.14 38.57% | -2.30 26.90% | -1.83 20.39% | |
operating cash flow per share | -1.05 - | -1.88 79.65% | -1.49 21.11% | -1.72 15.72% | -2.05 19.13% | -1.84 10.21% | |
payables turnover | 0.63 - | ||||||
receivables turnover | 6.06 - | ||||||
research and ddevelopement to revenue | 120.94 - | 174.71 44.46% | 60.04 65.63% | 12.76 78.74% | 7.57 40.65% | ||
return on tangible assets | -0.73 - | -0.62 14.63% | -1.55 150.73% | -0.34 78.15% | -0.38 11.12% | -0.43 14.88% | |
revenue per share | 0.02 - | 0.01 52.80% | 0.04 423.27% | 0.15 304.03% | 0.21 35.83% | ||
roe | 0.73 - | 0.65 9.96% | 0.69 5.23% | -0.42 160.61% | -0.50 19.97% | -0.61 22.58% | |
roic | 0.74 - | 1.20 62.64% | 0.70 41.19% | -0.33 146.73% | -0.41 23.56% | -0.51 24.71% | |
sales general and administrative to revenue | 24.10 - | 39.20 62.65% | 14.60 62.76% | 4.00 72.59% | 2.86 28.52% | ||
shareholders equity per share | -1.69 - | -3.28 93.60% | -3.30 0.56% | 7.53 328.64% | 4.59 39.07% | 2.98 35.05% | |
stock based compensation to revenue | 2.36 - | 6.15 160.17% | 6.75 9.74% | 1.67 75.22% | 1.17 29.94% | ||
tangible asset value | -15.94M - | -45.85M 187.56% | -104.95M 128.91% | 250.12M 338.33% | 171.51M 31.43% | 112.74M 34.26% | |
tangible book value per share | -1.69 - | -3.28 93.60% | -3.30 0.56% | 7.53 328.64% | 4.59 39.07% | 2.98 35.05% | |
working capital | 11.35M - | 27.24M 140.14% | 14.10M 48.26% | 167.83M 1,090.55% | 149.63M 10.85% | 85.07M 43.14% |
All numbers in USD (except ratios and percentages)